Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 12% YoY revenue growth and a 25% increase in net income, driven by strong product sales and effective cost management. EPS growth aligns with net income, and positive cash flow indicates strong financial health. Despite no updates on strategic initiatives or shareholder returns, the raised revenue guidance and decreased operating loss forecast are positive indicators. The market cap suggests moderate volatility, supporting a positive sentiment prediction.
Key Financial Performance
Revenue Supernus Pharmaceuticals reported a revenue of $175 million for Q4 2025, which represents a 12% increase year-over-year. This growth was primarily driven by strong sales of their flagship product, Trokendi XR, and the successful launch of a new product line.
Net Income The company achieved a net income of $25 million in Q4 2025, up from $20 million in Q4 2024, marking a 25% year-over-year increase. The improvement was attributed to higher revenue and effective cost management strategies.
Operating Expenses Operating expenses for Q4 2025 were $90 million, a 5% increase compared to the same period last year. The rise was due to increased investment in research and development for pipeline products.
Earnings Per Share (EPS) Earnings per share for Q4 2025 stood at $0.45, compared to $0.36 in Q4 2024, reflecting a 25% year-over-year growth. This was in line with the increase in net income.
Cash Flow The company reported a positive cash flow of $50 million for Q4 2025, which is a 10% increase from the previous year. This was driven by improved operational efficiency and higher revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: Management may make forward-looking statements regarding future events and the company's future performance. These statements involve risks and uncertainties, including those noted in the Risk Factors section of the company's latest SEC filings. Actual results may differ materially from those projected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Share Buyback Program: No specific mention of a share buyback program was made during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amsellem Piper
BofA Securities
CFO PM
Cantor Fitzgerald
Co Research
Conference Instructions
Cox Jefferies
Dec Senior
Director Timothy
Division Amsellem
Division Jack
Division Kristen
Division Pavan
Division Stacy
Division afternoon
EST Cox
Fitzgerald Co
Full Financial
Jack Khattar
Jack Padovano
Khattar Founder
Kristen Kluska
Ku TD
PM EST
Patel BofA
Pavan Patel
Pharmaceuticals Full
Research Division
Securities Research
Stacy Ku
conference ICR
SUPN Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call showed improved financial metrics, including reduced net loss and increased cash reserves. The company announced a collaboration agreement, which is typically positive. Despite increased expenses, the focus on product growth and strategic initiatives, like the DTC campaign and new supplier approval, suggests optimism. The Q&A revealed strong product adoption and growth potential, with positive analyst sentiment. Although some management responses lacked clarity, the overall outlook is positive, especially with the market cap indicating a strong reaction to these developments.
Pollard Banknote Limited (PBL:CA) Q4 2025 Earnings Call Transcript
Positive3-11
The company's financial performance shows strong revenue growth and a significant net income increase, alongside record full-year revenue. Although gross profit margins have decreased, management expects them to improve. The Q&A provides positive insights into future profitability, especially with Kansas iLottery moving towards profitability. Guidance adjustments indicate increased revenue expectations and reduced operating loss, contributing to a positive sentiment. However, the lack of specific guidance on some issues and ongoing regulatory challenges slightly temper the overall outlook. Given the market cap, the stock is likely to see a positive movement of 2% to 8%.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
SUPN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
